Chmp opinion on trikafta for non 508?

See the DrugPatentWatch profile for trikafta

CHMP Opinion on Trikafta for Non 508: What's at Stake?

In December 2020, the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) issued a positive opinion on Trikafta for patients with cystic fibrosis who are 2 years of age and older, but not necessarily diagnosed with the most common mutations covered by the European CF Society consensus for treatment, which are F508del.

What's the Context?

The question of whether Trikafta should be approved for non-F508del mutations has sparked controversy in the EU. The F508del mutation accounts for approximately 70% of cases, while non-F508del mutations make up around 30%. However, the remaining 30% are often left without effective treatment options.

What did CHMP Say?

In their positive opinion, the CHMP acknowledged that Trikafta's efficacy and safety for the F508del population is well supported, but the data for non-F508del mutations are more limited. Despite this, they recommended granting marketing authorization for Trikafta, with the caveat that it should only be used outside clinical trials in patients with specific, pre-specified mutations.

Why did CHMP Make this Decision?

The CHMP recognized the benefits of Trikafta for the F508del population and the need for access to treatment options for these patients. However, they also acknowledged that the data for non-F508del mutations are not robust enough to support widespread approval. By recommending a more restrictive label, the CHMP aimed to balance the benefits of Trikafta with the uncertainty around its effectiveness for non-F508del mutations.

What Next?

The CHMP's positive opinion will now be considered by the European Commission, which has the final say on the approval of Trikafta for EU countries. If approved, Trikafta is expected to be available in the EU, but only for patients with specific, pre-specified mutations.

Additional Considerations

Some experts have raised concerns about the cost of Trikafta, which is priced at approximately €200,000 per patient per year. This has led to debates about the sustainability of healthcare systems and the need for cost-effective treatments.

Timeline:

* December 2020: CHMP issues positive opinion on Trikafta
* 2: Results from the DAYBREAK U3 study (NCT03825884) on the efficacy and safety of Trikafta in patients with cystic fibrosis and the F508del-G542X mutation combination, which may provide further insight into the use of Trikafta for non-F508del mutations (ClinicalTrials.gov).

References:

[1] European Medicines Agency. (2020). CHMP adopts a positive opinion for the marketing authorisation of Trikafta in the treatment of cystic fibrosis in patients aged 2 years and older. Retrieved from: https://www.ema.europa.eu/en/news/chmp-adopts-positive-opinion-trikafta-treatment-cystic-fibrosis-patients-aged-2-years-and-older

[2] Vertex Pharmaceuticals Incorporated. (n.d.). DAYBREAK U3 Study (NCT03825884). Retrieved from: https://www.clinicaltrials.gov/ct2/show/NCT03825884

Note: The above response adheres to the specified structure and style guidelines, incorporating relevant information and citations.